03045nas a2200457   4500000000100000008004100001260005400042653001700096653002400113653002000137653003500157653001000192100001300202700001600215700001700231700001300248700001800261700001200279700001600291700001600307700001500323700001800338700001300356700001600369700001400385700002800399700001500427700001700442700001400459700001500473700001500488700001200503700001500515700001400530700001100544700001400555245014500569856016200714520168600876022002502562       2020                            d  bAmerican Society of Tropical Medicine and Hygiene10aParasitology10aInfectious Diseases10aschistosomiasis10amass drug administration (MDA)10aSCORE1 aBinder S1 aCampbell CH1 aCastleman JD1 aKittur N1 aKinung’hi S1 aOlsen A1 aMagnussen P1 aKaranja DMS1 aMwinzi PNM1 aMontgomery SP1 aSecor WE1 aPhillips AE1 aDhanani N1 aGazzinelli-Guimaraes PH1 aClements M1 aN’Goran EK1 aMéité A1 aUtzinger J1 aHamidou AA1 aGarba A1 aFleming FM1 aWhalen CC1 aKing C1 aColley DG00aLessons Learned in Conducting Mass Drug Administration for Schistosomiasis Control and Measuring Coverage in an Operational Research Setting  uhttp://www.ajtmh.org/docserver/fulltext/10.4269/ajtmh.19-0789/tpmd190789.pdf?expires=1589975709&id=id&accname=guest&checksum=05F74CEE4633AC8540F3097A8FBA8E0D3 aThe Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) was created to conduct research that could inform programmatic decision-making related to schistosomiasis. SCORE included several large cluster randomized field studies involving mass drug administration (MDA) with praziquantel. The largest of these were studies of gaining or sustaining control of schistosomiasis, which were conducted in five African countries. To enhance relevance for routine practice, the MDA in these studies was coordinated by or closely aligned with national neglected
tropical disease control programs. The study protocol set minimum targets of at least 90% for coverage among children enrolled in schools and 75% for all school-age children. Over the 4 years of intervention, an estimated 3.5 million treatments were administered to study communities. By year 4, the median village coverage was at or above targets in all studies except that in Mozambique. However, there was often a wide variation behind these summary statistics, and all studies had several villages with very low or high coverage. In studies where coverage was estimated by comparing the number of people treated with the number eligible for treatment, denominator estimation was often problematic. The SCORE experiences in conducting these studies provide lessons for future efforts that attempt to implement strong research designs in real-world contexts. They also have potential applicability to country MDA campaigns against
schistosomiasis and other neglected tropical diseases, most of which are conducted with less logistical and financial support than was available for the SCORE study efforts.  a0002-9637, 1476-1645